The PROBEAT trial is a prospective, multicentre phase III study led by Women’s Hospital of Zhejiang University Gynaecologic Oncology Group. Recruitment began on January 24, 2022, and is scheduled to end in December 2024.
The study schema is shown in Fig. 1. We plan to recruit 590 subjects with a HIR or IR of EEC. They will be randomly assigned at a 2:1 ratio to either the experimental arm or the standard arm. Patients in the experimental arm will receive molecular profile-based adjuvant treatment as follows: observation for the POLEmut subgroup, vaginal brachytherapy (VBT) for the MMRd or NSMP subgroups, and chemoradiotherapy for the p53abn profile subgroup. Adjuvant radiotherapy will be provided to the patients in the standard arm.